The following is a summary of “Factors associated with the detection of atrial fibrillation in patients with embolic stroke ...
Background Atrial fibrillation (AF) and acute myocardial infarction (AMI) share risk factors and are bidirectionally associated. Several studies found higher risks of outcomes in individuals with both ...
Boston Scientific Corporation (NYSE: BSX) today announced data supporting the use of the FARAPULSE™ Pulsed Field Ablation ...
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed ...
Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation By Boston Scientific Corporation Jan 16, 2025 ...
Boston Scientific Corp. reported positive data for two key atrial fibrillation therapies at AF Symposium 2025 on January 17.
GlobalData on MSN3d
Boston Scientific sees success in PFA device trialUS healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients ...
Risk for bleeding events is significantly affected by DOAC score in patients with atrial fibrillation who have received TAVR.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback